WO2007146943A2 - Nanoparticulate kinase inhibitor formulations - Google Patents
Nanoparticulate kinase inhibitor formulations Download PDFInfo
- Publication number
- WO2007146943A2 WO2007146943A2 PCT/US2007/071011 US2007071011W WO2007146943A2 WO 2007146943 A2 WO2007146943 A2 WO 2007146943A2 US 2007071011 W US2007071011 W US 2007071011W WO 2007146943 A2 WO2007146943 A2 WO 2007146943A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- less
- composition
- nanoparticulate
- ammonium chloride
- chloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the present invention relates to kinase inhibitor compounds and compositions useful in the treatment or prevention of disease or disorders such as myeloproliferative diseases, leukemias, and related diseases or conditions. More specifically, the invention relates to nanoparticulate kinase inhibitor compositions, such as nanoparticulate LS 104 compositions having an effective average particle size of less than about 2000 nm. The invention also relates to methods of making and using such nanoparticulate compositions.
- Leukemias are cancers of the bone marrow and blood. They are characterized by the uncontrolled accumulation of abnormal blood cells. Examples include acute lymphoblastic leukemia (ALL), Chronic Myelogenous Leukemia (CML) and Acute Myelogenous Leukemia (AML). The most common type of leukemia is acute myeloid leukemia (AML) with an estimated 12,000 new cases annually in the United States. AML occurs mostly in adults over the age of 40 and with an average age of occurrence of 65. Cancers such as AML represent an area of high, unmet medical need; current treatments for AML are characterized by poor long-term response rates with fewer than 20 percent of adult patients surviving after diagnosis.
- ALL acute lymphoblastic leukemia
- CML Chronic Myelogenous Leukemia
- AML Acute Myelogenous Leukemia
- AML acute myeloid leukemia
- FLT3 Several kinds of mutation have been found in AML; no single one is at fault, and it appears that at least two are required to trigger disease. However, a mutation in the receptor tyrosine kinase FLT3 occurs in about one third of AML patients and carries a particularly poor prognosis. FLT3 conveys a proliferation signal and is normally expressed early in the development of bone marrow stem cells, but in its mutated form, it remains active and helps leukemic cells flourish. Several groups have been working to identify compounds that could inhibit FLT3.
- CML and some ALLs are chromosomal translocation that occurs between chromosome 22 and chromosome 9, resulting in an altered chromosome 22 which is known as the "Philadelphia chromosome.”
- Philadelphia chromosome is the result of a portion of chromosome 9 that includes a portion of the Abelson proto-oncogene (AbI), being translocated to chromosome 22.
- AbI Abelson proto-oncogene
- the breakpoints on chromosome 9 may vary, the breakpoints on chromosome 22 are relatively clustered.
- Bcr breakpoint cluster region
- Bcr- AbI fused gene that results from the translocation.
- All forms of the fusion protein include a portion of the Abelson protein having tyrosine kinase activity.
- the tyrosine kinase activity is constitutive in the Bcr-Abl fusion protein; the negative regulators of this activity no longer function in the fusion protein.
- This constitutive kinase activity has been shown to activate various signal transduction pathways leading to uncontrolled cell growth and division (e.g., by promoting cell proliferation and inhibiting apoptosis).
- Bcr-Abl may cause undifferentiated blood cells to proliferate massively and fail to mature.
- Non-CML myeloproliferative diseases such as polycythemia vera (PV), essential thrombocythemia (ET), and chronic idiopathic myelofibrosis (IMF) and as of yet unclassified myeloproliferative diseases (MPD-NC) are characterized by an aberrant increase in blood cells. See e.g., Vainchenker and Constantinescu, Hematology (American Society of Hematology) 195-200 (2005). This increase is generally initiated by a spontaneous mutation in a multipotent hematopoetic stem cell located in the bone marrow. Id.
- the stem cell Due to the mutation, the stem cell produces far more blood cells of a particular lineage than normal, resulting in the overproduction of cells such as erythroid cells, megakaryocytes, granulocytes and monocytes.
- Some symptoms common to patients with MPD include enlarged spleen, enlarged liver, elevated white, red and/or platelet cell count, blood clots (thrombosis), weakness, dizziness and headache.
- Diseases such as PV, ET and IMF may presage leukemia, however the rate of transformation (e.g., to blast crisis) differs with each disease. Id. [0006]
- the specific gene and concomitant mutation or mutations responsible for many MPDs is not known.
- J. Biol. 1 a dominant gain of function mutation in the Janus kinase 2 (JAK2) gene, a cytoplasmic, nonreceptor tyrosine kinase, has been identified in a number of MPDs. For example, this mutation has been reported in up to 97% of patients with PV, and in greater than 40% of patients with either ET or IMF. See e.g., Baxter, et al., Lancet 365:1054-1060 (2005); James, et al., Nature 438: 1144-1148 (2005); Zhao, et al., J. Biol.
- the Janus kinases are a family of tyrosine kinases that play a role in cytokine signaling.
- JAK2 kinase acts as an intermediary between membrane-bound cytokine receptors such as the erythropoietin receptor (EpoR), and down-stream members of the signal transduction pathway such as STAT5 (Signal Transducers and Activators of Transcription protein 5).
- EpoR erythropoietin receptor
- STAT5 Signal Transduction pathway
- JAK2 is activated when cytokine receptor/ligand complexes phosphorylate the associated JAK2 kinase. Id. JAK2 can then phosphorylate and activate its substrate molecule, for example STAT5, which enters the nucleus and interacts with other regulatory proteins to affect transcription. Id.
- Treatment of leukemias and myeloproliferative disorders may involve drug therapy (e.g., chemotherapy), bone marrow transplants, radiation therapy, or combinations thereof.
- drug therapy e.g., chemotherapy
- bone marrow transplants e.g., bone marrow transplants
- radiation therapy e.g., radiation therapy
- kinase inhibitors e.g., one kinase inhibitor called "imatinib mesylate” (i.e., STI571 or 2- phenylaminopyrimidine) has proven effective for treating CML and ALL.
- Imatinib is marketed as a drug under the tradename "Gleevec" or "Glivec.”
- LS 104 a styrylacrylonitirle compound, which is chemically known as (E,E)-2-(Benzylaminocarbonyl)-3-(3,4- dihydroxystyryl)acrylonitrile.
- LS 104 has an empiric formula Of C 1P H 16 O 3 N 2 , with a molecular weight of 320.34.
- the chemical structure of LS 104 is:
- Styrylacrylonitrile compounds such as LS104 are useful in treating a variety of cell proliferative disorders such as cancer. Styrylacrylonitrile compounds are disclosed, for
- Strylacrylonitrile compounds such as LS 104 act, generally, by inhibiting abnormal cellular signaling that may be specific to the growth of cancer cells.
- LS 104 functions as a small molecule kinase inhibitor, specifically, as a tyrosine kinase inhibitor. By blocking the action of specific kinases, LS 104 targets cancer cell pathways in contrast to many chemotherapy compounds, which attack cancerous and non-cancerous cells alike causing serious side effects.
- LS 104 is a member of a new class of synthetic, small molecule, non-ATP competitive kinase inhibitors. Most kinase inhibitors currently in development for use as a therapeutic compete with adenosine triphosphate (ATP), the cell's energy source. Thus, LS 104 has the potential of being effective in restricting cancer development with a significantly lower toxicity than chemotherapy currently used in cancer treatment.
- ATP adenosine triphosphate
- AML Acute Myelogenous Leukemia
- ALL Acute Lymphocytic Leukemia
- CML Chronic Myelogenous Leukemia
- PV polycythemia vera
- ET essential thrombocythemia
- MMM myeloid metaplasia with myelofibrosis
- IM idiopathic myelofibrosis
- LS 104 has been shown to inhibit both Janus Kinase 2 ("JAK2”) activity, a dominant gain of function mutation identified in numerous myeloproliferative disorders, and Bcr-Abl tyrosine kinase activity, a product of the translocation event known as the "Philadelphia Chromosome,” which is present in various
- LS 104 may not become readily bioavailable when administered.
- Such a formulation would be faster acting, thereby providing relief to a subject suffering from diseases or disorders involving unregulated, overactive kinase activity, such as tyrosine kinase activity.
- diseases or disorders involving unregulated, overactive kinase activity such as tyrosine kinase activity.
- Leukemias, myeloproliferative disorders, or other blood related cancers, or diseases are examples of such disorders.
- Such a formulation may also overcome other problems associated with conventional drug formulations. The present invention satisfies these needs.
- the present invention then, relates to nanoparticulate kinase inhibitor compositions, such as nanoparticulate LS 104, or a salt or derivative thereof, compositions for the treatment of blood cancers and related diseases, disorders, conditions and symptoms.
- nanoparticulate kinase inhibitor compositions such as nanoparticulate LS 104, or a salt or derivative thereof, compositions for the treatment of blood cancers and related diseases, disorders, conditions and symptoms.
- Nanoparticulate active agent compositions are particles consisting of a poorly soluble therapeutic or diagnostic agent having adsorbed onto the surface thereof a non-crosslinked surface stabilizer.
- the '684 patent does not describe nanoparticulate compositions of kinase inhibitors such as LS 104.
- Nanoparticulate active agent compositions are also described, for example, in U.S. Patent Nos. 5,298,262 for "Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization;" 5,302,401 for “Method to Reduce Particle Size Growth During Lyophilization;” 5,318,767 for “X-Ray Contrast Compositions Useful in Medical Imaging;” 5,326,552 for “Novel Formulation For Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;” 5,328,404 for “Method of X-Ray Imaging Using Iodinated Aromatic Propanedioates;” 5,336,507 for "Use of Charged Phospholipids to Reduce Nanoparticle Aggregation;” 5,340,564 for
- WASH 1899464 1 "Formulations Comprising Olin 10-G to Prevent Particle Aggregation and Increase Stability;" 5,346,702 for "Use of Non-Ionic Cloud Point Modifiers to Minimize Nanoparticulate Aggregation During Sterilization;" 5,349,957 for “Preparation and Magnetic Properties of Very Small Magnetic-Dextran Particles;” 5,352,459 for “Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization;” 5,399,363 and 5,494,683, both for "Surface Modified Anticancer Nanoparticles;” 5,401,492 for "Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents;” 5,429,824 for “Use of Tyloxapol as a Nanoparticulate Stabilizer;” 5,447,710 for "Method for Making Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular
- 20070065374 for "Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations;" U.S. Patent Publication No. 20070059371 for “Nanoparticulate ebastine formulations;” U.S. Patent Publication No. 20070048378 for "Nanoparticulate anticonvulsant and immunosuppressive compositions;” U.S. Patent Publication No. 20070042049 for "Nanoparticulate benidipine compositions;” U.S. Patent Publication No. 20070015719 for "Nanoparticulate clarithromycin formulations;” U.S. Patent Publication No. 20070003628 for "Nanoparticulate clopidogrel formulations;” U.S.
- Patent Publication No. 20070003615 for "Nanoparticulate clopidogrel and aspirin combination formulations;” U.S. Patent Publication No. 20060292214 for “Nanoparticulate acetaminophen formulations;” U.S. Patent Publication No. 20060275372 for "Nanoparticulate imatinib mesylate formulations;” U.S. Patent Publication No. 20060246142 for "Nanoparticulate quinazoline derivative formulations," U.S. Patent Publication No. 20060246141 for "Nanoparticulate lipase inhibitor formulations," U.S. Patent Publication No.
- 20060216353 for "Nanoparticulate corticosteroid and antihistamine formulations," U.S. Patent Publication No. 20060210639 for” Nanoparticulate bisphosphonate compositions," U.S. Patent Publication No. 20060210638 for "Injectable compositions of nanoparticulate immunosuppressive compounds," U.S. Patent Publication No. 20060204588 for "Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof," U.S. Patent Publication No. 20060198896 for "Aerosol and injectable formulations of nanoparticulate benzodiazepine," U.S. Patent Publication No.
- WASH 1899464 1 beclomethasone dipropionate compositions;" U.S. Patent Publication No. 20040033267 for "Nanoparticulate compositions of angiogenesis inhibitors;” U.S. Patent Publication No. 20040033202 for “Nanoparticulate sterol formulations and novel sterol combinations;” U.S. Patent Publication No. 20040018242 for "Nanoparticulate nystatin formulations;” U.S. Patent Publication No. 20040015134 for "Drug delivery systems and methods;” U.S. Patent Publication No. 20030232796 for "Nanoparticulate polycosanol formulations & novel polycosanol combinations;” U.S. Patent Publication No.
- Amorphous small particle compositions are described, for example, in U.S. Patent Nos. 4,783,484 for "Particulate Composition and Use Thereof as Antimicrobial Agent;” 4,826,689 for “Method for Making Uniformly Sized Particles from Water-Insoluble Organic Compounds;” 4,997,454 for “Method for Making Uniformly-Sized Particles From Insoluble Compounds;” 5,741,522 for "Ultrasmall, Non-aggregated Porous Particles of Uniform Size for Entrapping Gas Bubbles Within and Methods;” and 5,776,496, for "Ultrasmall Porous Particles for Enhancing Ultrasound Back Scatter.” These are also specifically incorporated herein by reference.
- WASH 1899464 1 improved efficacy and/or are suitable for administration such as parenteral administration.
- the present invention fills that need.
- the present invention then, relates to nanoparticulate compositions comprising a kinase inhibitors such as LS 104, which may be useful in the treatment and prevention of diseases and disorders, such as CML, AML, ALL, myeloproliferative diseases, and other blood-related cancers and diseases.
- a kinase inhibitors such as LS 104
- diseases and disorders such as CML, AML, ALL, myeloproliferative diseases, and other blood-related cancers and diseases.
- the present invention relates to stable nanoparticulate compositions comprising a kinase inhibitor, such as LS 104, or a salt or derivative thereof, and at least one surface stabilizer.
- a kinase inhibitor such as LS 104
- the surface stabilizer may be associated with the surface of the particles, for example, the surface stabilizer may be adsorbed onto the surface of the LS 104 particle.
- the drug nanoparticles have an effective average particle size of less than about 2000 nm.
- compositions may include LS 104 particles which are in a crystalline phase, an amorphous phase, a semi-crystalline phase, a semi-amorphous phase and mixtures thereof.
- the compositions may include one or more surface stabilizers.
- some compositions may include at least one primary and at least one secondary surface stabilizer.
- Exemplary surface stabilizers include, but are not limited to non-ionic surface stabilizers, ionic surface stabilizers, anionic surface stabilizers, cationic surface stabilizers, zwitterionic surface stabilizers and combinations thereof.
- the invention also relates to compositions comprising nanoparticulate kinase inhibitors such as LS 104 or a salt or derivative thereof, at least one surface stabilizer, and optionally one or more pharmaceutically acceptable excipients, carriers, and optionally one or more active agents useful for the treatment of cancers such as leukemias, myeloproliferative diseases and related disorders, or a combination thereof.
- nanoparticulate kinase inhibitors such as LS 104 or a salt or derivative thereof
- at least one surface stabilizer and optionally one or more pharmaceutically acceptable excipients, carriers, and optionally one or more active agents useful for the treatment of cancers such as leukemias, myeloproliferative diseases and related disorders, or a combination thereof.
- compositions of the invention comprising a nanoparticulate kinase inhibitor, such as LS 104 or a salt or derivative thereof, are proposed to exhibit improved pharmacokinetic profiles as compared to conventional kinase inhibitor (e.g., LS104) compositions.
- a nanoparticulate kinase inhibitor such as LS 104 or a salt or derivative thereof
- the C max and/or AUC of the nanoparticulate compositions may be greater than the C max and/or AUC for conventional compositions administered at the same dosage while the T max may be lower; any combination of an improved C max , AUC and T max profile may be exhibited by the nanoparticulate LSO 14 compositions as compared to
- the LS 104 compositions may not produce significantly different absorption levels when administered under fed as compared to fasting conditions.
- the nanoparticulate LS 104 compositions exhibit improved bioavailability as compared to conventional LS 104 compositions.
- the nanoparticulate LS 104 compositions may redisperse such that the particles have an effective average particle size of less than about 2 microns.
- the invention also relates to methods of making nanoparticulate compositions including an kinase inhibitor, such as LS 104 or salt or derivative thereof.
- the methods may include contacting particles of an LS 104 with at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate LS 104 composition having an effective average particle size of less than about 2000 nm.
- the invention also relates to methods of treatment using the nanoparticulate LS 104 compositions.
- a composition comprising a nanoparticulate LS 104 or salt or derivative thereof, having an effective average particle size of less than about 2000 nm, and at least one surface stabilizer, may be administered to a subject.
- the composition may be formulated for parental injection (e.g., intravenous, intramuscular, or subcutaneous), in a therapeutically effective amount.
- the injectable formulation may provide a high LS 140 concentration in a small volume to be injected.
- administration comprises a bolus injection of a kinase inhibitor, such as LS 140, with one continuous fast injection, rather than a slow infusion of the drug.
- a kinase inhibitor such as LS 140
- the composition may be administered to treat myeloproliferative disorders, diseases, symptoms or conditions associated with myeloproliferative disorders, and cancers such as leukemias like CML, AML and ALL.
- the subject may be suffering from such a disease, disorder, symptom or condition.
- Other methods of treatment using the nanoparticulate compositions of the invention are known to those of skill in the art.
- the present invention is directed to compositions comprising at least one nanoparticulate kinase inhibitor, such as LS 104 or a salt or derivative thereof, and at least one surface stabilizer.
- the surface stabilizer may be adsorbed or associated with the surface of the drug.
- the LS 104 particles, or a salt or derivative thereof have an effective average particle size of less than about 2000 nm.
- compositions comprising at least one nanoparticulate kinase inhibitor, such as LS 104, as compared to conventional non-nanoparticulate (microcrystalline or solubilized) formulations of the same kinase inhibitor include, but are not limited to: (1) smaller tablet or other solid dosage form size; (2) smaller doses of drug required to obtain the same pharmacological effect; (3) increased bioavailability; (4) improved pharmacokinetic profiles; (5) substantially similar pharmacokinetic profiles when administered in the fed versus the fasted state; (6) bioequivalency when administered in the fed versus the fasted state; (7) increased rate of absorption of nanoparticulate compositions; (8) an increased rate of dissolution; and (9) the kinase inhibitor compositions can be used in conjunction with other active agents useful in the treatment of myeloproliferative disorders, cancers such as leukemias and related disorders, diseases, symptoms, or conditions.
- the present invention also includes compositions comprising at least one nanoparticulate kinase inhibitors, such as LS 104 or a salt or derivative thereof, together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
- the compositions can be formulated for parental injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, bioadhesive, vaginal, nasal, rectal, ocular, local (powders, ointments, or drops), buccal, intracisternal, intraperitoneal, or topical administrations, and the like.
- a preferred dosage form of the invention is an injectable dosage form, although any pharmaceutically acceptable dosage form can be utilized.
- the injectable formulation may provide a high LS 140 concentration in a small volume to be injected.
- administration comprises a bolus injection of a kinase inhibitor, such as LS 140, with one continuous fast injection, rather than a slow infusion of the drug.
- Exemplary solid dosage forms include, but are not limited to, tablets, capsules, sachets, lozenges, powders, pills, or granules, and the solid dosage form can be, for example,
- WASH 1899464 1 a fast melt dosage form, controlled release dosage form, lyophilized dosage form, delayed release dosage form, extended release dosage form, pulsatile release dosage form, mixed immediate release and controlled release dosage form, or a combination thereof.
- the term "effective average particle size,” as used herein, means that at least about 50% of the nanop articulate kinase inhibitor particles, such as LS104, have a size of less than about 2000 nm (by weight or by other suitable measurement, such as by volume, number, etc.), when measured by, for example, sedimentation flow fractionation, photon correlation spectroscopy, light scattering, disk centrifugation, and other techniques known to those of skill in the art.
- stable connotes, but is not limited to one or more of the following parameters: (1) the particles do not appreciably flocculate or agglomerate due to interparticle attractive forces or otherwise significantly increase in particle size over time; (2) the physical structure of the particles is not altered over time, such as by conversion from an amorphous phase to a crystalline phase; (3) the particles are chemically stable; and/or (4) where the kinase inhibitor has not been subject to a heating step at or above the melting point of the kinase inhibitor particles in the preparation of the nanoparticles of the present invention.
- non-nanoparticulate active agent shall mean an active agent which is solubilized or which has an effective average particle size of greater than about 2000 nm. Nanoparticulate active agents as defined herein have an effective average particle size of less than about 2000 nm.
- pooledly water soluble drugs refers to those drugs that have a solubility in water of less than about 30 mg/ml, less than about 20 mg/ml, less than about 10 mg/ml, or less than about 1 mg/ml.
- the phrase "therapeutically effective amount” shall mean that drug dosage that provides the specific pharmacological response for which the drug is administered in a significant number of subjects in need of such treatment. It is emphasized that a therapeutically effective amount of a drug that is administered to a particular subject in
- WASH 1899464 1 a particular instance will not always be effective in treating the conditions/diseases described herein, even though such dosage is deemed to be a therapeutically effective amount by those of skill in the art.
- myeloproliferative disease or “myeloproliferative disorder” is meant to include non-lymphoid dysplastic or neoplastic conditions arising from a haematopoietic stem cell or its progeny.
- MPD patient includes a patient who has been diagnosed with an MPD.
- Myeloproliferative disease is meant to encompass the specific, classified types of myeloproliferative diseases including polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF).
- PV polycythemia vera
- ET essential thrombocythemia
- IMF idiopathic myelofibrosis
- hypereosinophilic syndrome HES
- chronic neutrophilic leukemia CNL
- myelofibrosis with myeloid metaplasia MMM
- chronic myelomonocytic leukemia CMML
- Myeloproliferative disease is also meant to encompass any unclassified myeloproliferative diseases (UMPD or MPD-NC).
- compositions of the invention comprising at least one kinase inhibitor, such as LS 104, of the invention are contemplated to exhibit increased bioavailability as compared to the same non-nanop articulate kinase inhibitor. Moreover, the compositions of the invention are expected to require smaller doses, and smaller tablet or other solid dosage form size as compared to prior conventional non-nanoparticulate formulations of the same kinase inhibitor to achieve the same pharmacological effect.
- the increased bioavailability is significant because it means that the nanoparticulate kinase inhibitor dosage form will likely exhibit significantly greater drug absorption.
- compositions comprising at least one nanoparticulate kinase inhibitor, such as LS 104, having a desirable pharmacokinetic profile when administered to mammalian subjects.
- the desirable pharmacokinetic profile of the compositions comprising at least one nanoparticulate kinase inhibitor such as LS 104 includes, but is not limited to: (1) a C max for a kinase inhibitor, such as LS 104, when assayed in the plasma of a mammalian subject following administration, that is preferably greater than
- WASH 1899464 1 the C max for a non-nanoparticulate formulation of the same kinase inhibitor, administered at the same dosage; and/or (2) an AUC for an kinase inhibitor, such as LS 104, when assayed in the plasma of a mammalian subject following administration, that is preferably greater than the AUC for a non-nanoparticulate formulation of the same kinase inhibitor, administered at the same dosage; and/or (3) a T max for a kinase inhibitor, such as LS 104, when assayed in the plasma of a mammalian subject following administration, that is preferably less than the T max for a non-nanoparticulate formulation of the same kinase inhibitor, administered at the same dosage.
- the desirable pharmacokinetic profile is the pharmacokinetic profile measured after the initial dose of a kinase inhibitor, such as LS 104.
- a composition comprising a nanoparticulate kinase inhibitor, such as LS 104 exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same kinase inhibitor, administered at the same dosage, a T max not greater than about 90%, not greater than about 80%, not greater than about 70%, not greater than about 60%, not greater than about 50%, not greater than about 30%, not greater than about 25%, not greater than about 20%, not greater than about 15%, not greater than about 10%, or not greater than about 5% of the T max exhibited by the non-nanoparticulate kinase inhibitor formulation.
- the composition comprising a nanoparticulate kinase inhibitor exhibits in comparative pharmacokinetic testing with a non- nanoparticulate formulation of the same kinase inhibitor, administered at the same dosage, a C max which is at least about 50%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600%, at least about 700%, at least about 800%, at least about 900%, at least about 1000%, at least about 1100%, at least about 1200%, at least about 1300%, at least about 1400%, at least about 1500%, at least about 1600%, at least about 1700%, at least about 1800%, or at least about 1900% greater than the C max exhibited by the non-nanoparticulate kinase inhibitor formulation.
- a C max which is at least about 50%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600%, at least about 700
- the composition comprising a nanoparticulate kinase inhibitor exhibits in comparative pharmacokinetic testing with a non- nanoparticulate formulation of the same kinase inhibitor, administered at the same dosage, an AUC which is at least about 25%, at least about 50%, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at least about
- an AUC which is at least about 25%, at least about 50%, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at
- WASH 1899464 1 least about 800%, at least about 850%, at least about 900%, at least about 950%, at least about 1000%, at least about 1050%, at least about 1100%, at least about 1150%, or at least about 1200% greater than the AUC exhibited by the non-nanop articulate kinase inhibitor formulation.
- the T max of the kinase inhibitor, such as LS 104 when assayed in the plasma of the mammalian subject, is less than about 6 to about 8 hours. In other embodiments of the invention, the T max of the LS 104 is less than about 6 hours, less than about 5 hours, less than about 4 hours, less than about 3 hours, less than about 2 hours, less than about 1 hour, or less than about 30 minutes after administration.
- the desirable pharmacokinetic profile is the pharmacokinetic profile measured after the initial dose of an kinase inhibitor, such as LS 104.
- the compositions can be formulated in any way as described herein and as known to those of skill in the art.
- the invention encompasses compositions comprising at least one nanoparticulate kinase inhibitor, such as LS 104, wherein the pharmacokinetic profile of the kinase inhibitor is not substantially affected by the fed or fasted state of a subject ingesting the composition. This means that there is no substantial difference in the quantity of drug absorbed (AUC), the rate of drug absorption (C max ), or the length of time to C max (T max ), when the nanoparticulate kinase inhibitor compositions are administered in the fed versus the fasted state.
- AUC the quantity of drug absorbed
- C max rate of drug absorption
- T max the length of time to C max
- the difference in absorption (AUC) or C max of the nanoparticulate kinase inhibitor compositions of the invention when administered in the fed versus the fasted state, preferably is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
- the invention also encompasses a composition comprising a nanoparticulate kinase inhibitor, such as LS 104, in which administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state.
- the invention encompasses compositions comprising a nanoparticulate kinase inhibitors, such as LS 104, wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state, in particular as defined by C max and AUC guidelines given by the U.S. Food and Drug Administration and the corresponding European regulatory agency (EMEA). Under U.S.
- compositions comprising at least one nanoparticulate kinase inhibitor, such as LS 104, or a salt or derivative thereof, are proposed to have unexpectedly dramatic dissolution profiles. Rapid dissolution of an administered active agent is preferable, as faster dissolution generally leads to greater bioavailability and faster onset of action. To improve the dissolution profile and bioavailability of the kinase inhibitors it would be useful to increase the drug's dissolution so that it could attain a level close to 100%.
- the kinase inhibitors such as LS 104, compositions of the invention preferably have a dissolution profile in which within about 5 minutes at least about 20% of the composition is dissolved. In other embodiments of the invention, at least about 30% or at least about 40% of the kinase inhibitor composition is dissolved within about 5 minutes. In yet other embodiments of the invention, preferably at least about 40%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the kinase inhibitor composition is dissolved within about 10 minutes. Finally, in another embodiment of the invention, preferably at least about 70%, at least about 80%, at least about 90%, or at least about 100% of the kinase inhibitor composition is dissolved within 20 minutes.
- Dissolution is preferably measured in a medium which is discriminating.
- a discriminating dissolution medium is one that will produce two very different dissolution curves for two products having very different dissolution profiles in gastric juices; i.e., the dissolution medium is predictive of the in vivo dissolution of a composition.
- An exemplary dissolution medium is an aqueous medium containing the surfactant sodium lauryl sulfate at 0.025 M. Determination of the amount dissolved can be carried out by spectrophotometry. The rotating blade method (European Pharmacopoeia) can be used to measure dissolution.
- compositions comprising at least one nanoparticulate kinase inhibitor, such as LS 104 or a salt or derivative thereof, is that the compositions redisperse such that the effective average particle size of the redispersed kinase inhibitor particles is less than about 2 microns. This is significant, as upon administration, if the kinase inhibitor particles of the compositions of the present invention agglomerated or did not redisperse to a substantially nanoparticulate size, then the dosage form may lose the benefits afforded by formulating the kinase inhibitors into a nanoparticulate size. [0062] This is because nanoparticulate active agent compositions benefit from the small particle size of the active agent.
- the active agent does not disperse into the small particle sizes upon administration, then "clumps" or agglomerated active agent particles are formed, owing to the extremely high surface free energy of the nanoparticulate system and the thermodynamic driving force to achieve an overall reduction in free energy. With the formulation of such agglomerated particles, the bioavailability of the dosage form may fall well below that observed with the liquid dispersion form of the nanoparticulate active agent.
- compositions comprising at least one nanoparticulate kinase inhibitor, such as LS 104, of the invention exhibit dramatic redispersion of the nanoparticulate kinase inhibitor particles upon administration to a mammal, such as a human or animal, as demonstrated by reconstitution/ redispersion in a biorelevant aqueous media such that the effective average particle size of the redispersed kinase inhibitor particles is less than about 2 microns.
- biorelevant aqueous media can be any aqueous media that exhibit the desired ionic strength and pH, which form the basis for the biorelevance of the media.
- the desired pH and ionic strength are those that are representative of physiological conditions found in the human body.
- Such biorelevant aqueous media can be, for example, aqueous electrolyte solutions or aqueous solutions of any salt, acid, or base, or a combination thereof, which exhibit the desired pH and ionic strength.
- Biorelevant pH is well known in the art.
- the pH ranges from slightly less than 2 (but typically greater than 1) up to 4 or 5.
- the pH can range from 4 to 6, and in the colon it can range from 6 to 8.
- Biorelevant ionic strength is also well known in the art. Fasted state gastric fluid has an ionic strength of about 0. IM while fasted state intestinal fluid has an ionic strength of about 0.14. See e.g. , Lindahl et al., "Characterization of Fluids from the Stomach and Proximal Jejunum in Men and Women," Pharm. Res., 14 (4): 497-502 (1997).
- pH and ionic strength of the test solution is more critical than the specific chemical content. Accordingly, appropriate pH and ionic strength values can be obtained through numerous combinations of strong acids, strong bases, salts, single or multiple conjugate acid-base pairs ⁇ i.e., weak acids and corresponding salts of that acid), monoprotic and polyprotic electrolytes, etc.
- Representative electrolyte solutions can be, but are not limited to, HCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and NaCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and mixtures thereof.
- electrolyte solutions can be, but are not limited to, about 0.1 M HCl or less, about 0.01 M HCl or less, about 0.001 M HCl or less, about 0.1 M NaCl or less, about 0.01 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof.
- Electrolyte concentrations of 0.001 M HCl, 0.01 M HCl, and 0.1 M HCl correspond to pH 3, pH 2, and pH 1, respectively.
- a 0.01 M HCl solution simulates typical acidic conditions found in the stomach.
- a solution of 0.1 M NaCl provides a reasonable approximation of the ionic strength conditions found throughout the body, including the gastrointestinal fluids, although concentrations higher than 0.1 M may be employed to simulate fed conditions within the human GI tract.
- Exemplary solutions of salts, acids, bases or combinations thereof, which exhibit the desired pH and ionic strength include but are not limited to phosphoric acid/phosphate salts + sodium, potassium and calcium salts of chloride, acetic acid/acetate salts + sodium, potassium and calcium salts of chloride, carbonic acid/bicarbonate salts + sodium, potassium and calcium salts of chloride, and citric acid/citrate salts + sodium, potassium and calcium salts of chloride.
- the redispersed particles of a kinase inhibitor such as LS 104 or a salt or derivative thereof (redispersed in water, a biorelevant
- WASH 1899464 1 media or any suitable redispersion media
- WASH 1899464 1 media have an effective average particle size of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 990 nm, less than about 980 nm, less than about 970 nm, less than about 960 nm, less than about 950 nm, less than about 940 nm, less than about 930 nm, less than about 920 nm, less than about 910 nm, less than about 900 nm, less than about 890 nm, less than about 880 nm, less than about 870 nm, less than about 860 nm, less than about 850 nm, less
- compositions comprising at least one nanoparticulate kinase inhibitor can additionally comprise one or more compounds useful in the treatment of cancers such as leukemias or other related diseases, disorders, conditions or symptoms, or the kinase inhibitor compositions can be administered in conjunction with such a compound.
- Nanoparticulate kinase inhibitor compositions, such as LS 104 may provide broad opportunities for use in combination with other kinase inhibitors, such as Gleevec®, as well as current standard chemotheraphy treatments, bone marrow transplants, etc.
- the invention provides compositions comprising particles of at least one kinase inhibitor, such as LS 104 or a salt or derivative thereof, and at least one surface stabilizer.
- the surface stabilizers preferably are adsorbed on, or associated with, the surface of the LS 104 particles.
- Surface stabilizers especially may physically adhere on, or associate with, the surface of the nanoparticulate kinase inhibitor particles, but ideally do not chemically react with the particles of a kinase inhibitor (such as LS 104) or itself.
- Individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular cross-linkages.
- the present invention also includes kinase inhibitors such as LS 104, (or a salt or derivative thereof), compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
- the compositions can be formulated for parenteral injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, vaginal, nasal, rectal, ocular, local (powders, ointments or drops), buccal, intracisternal, intraperitoneal, or topical administration, and the like.
- compositions of the invention comprise particles of at least one kinase inhibitor, such as LS 104 or a salt or derivative thereof.
- the particles can be in a crystalline phase, semi-crystalline phase, amorphous phase, semi-amorphous phase, or a combination thereof.
- a surface stabilizer for a kinase inhibitor such as LS 104 is non-trivial. Accordingly, the present invention is directed to the surprising discovery that nanoparticulate kinase inhibitor compositions can be made.
- Combinations of more than one surface stabilizers can be used in the invention.
- Useful surface stabilizers which can be employed in the invention include, but are not limited to, known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants.
- Exemplary surface stabilizers include nonionic and ionic (e.g. , anionic, cationic, and zwitterionic) surfactants or compounds.
- surface stabilizers include albumin, including but not limited to human serum albumin and bovine albumin, hydroxypropyl methylcellulose (now known as hypromellose), hydroxypropylcellulose, polyvinylpyrrolidone, sodium lauryl sulfate, dioctylsulfosuccinate, gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tween ® products such as e.g., Tween ® products such as
- compositions of the invention can be formulated to be phospholipid-free.
- Examples of useful cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethylmethacrylate trimethylammoniumbromide bromide (PMMTMABr), hexyldesyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate.
- cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, hydroxyethyl ammonium chloride or bromide, coconut dimethyl hydroxyethyl ammonium chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy) 4 ammonium chloride or bromide, N-al
- WASH 1899464 1 didecyldimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(Ci 2 -i 4 ) dimethyl 1-naphthylmethyl ammonium chloride and dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C 12 , C 1S , C 17 trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyldimethylammonium halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromid
- Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation (Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry (Marcel Dekker, 1991); and J. Richmond, Cationic Surfactants: Organic Chemistry, (Marcel Dekker, 1990).
- Nonpolymeric surface stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quarternary ammonium compounds of the formula NR 1 R 2 R 3 R 4 ⁇ .
- benzalkonium chloride a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammoni
- two OfR 1 -R 4 are CH 3 , one OfR 1 -R 4 is C 6 H 5 CH 2 , and one Of R 1 -R 4 is an alkyl chain of nineteen carbon atoms or more;
- two OfR 1 -R 4 are CH 3 , one of R 1 -R 4 is C 6 H 5 CH 2 , and one of R 1 -R 4 comprises at least one heteroatom;
- R 1 -R 4 two Of R 1 -R 4 are CH 3 , one of R 1 -R 4 is C 6 H 5 CH 2 , and one of R 1 -R 4 comprises at least one halogen;
- R 1 -R 4 two Of R 1 -R 4 are CH 3 , one of R 1 -R 4 is C 6 H 5 CH 2 , and one of R 1 -R 4 comprises at least one cyclic fragment;
- Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydro fluoride, chlorallylmethenamine chloride (Quaternium-15), distearyldimonium chloride
- the surface stabilizers may be a copovidone (e.g., Plasdone
- S630 which is a random copolymer of vinyl acetate and vinyl pyrrolidone) and/or docusate sodium.
- the surface stabilizers are commercially available and/or can be prepared by techniques known in the art. Most of these surface stabilizers are known pharmaceutical excipients and are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 2000), specifically incorporated by reference.
- compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients.
- excipients are known in the art.
- filling agents include lactose monohydrate, lactose anhydrous, and various starches;
- binding agents include various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel ® PHlOl and Avicel ® PH 102, micro crystalline cellulose, and silicified microcrystalline cellulose (ProSolv SMCCTM).
- Suitable lubricants including agents that act on the flowability of the powder to be compressed, may include colloidal silicon dioxide, such as Aerosil ® 200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel.
- sweeteners may include any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame.
- sweeteners may include any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame.
- flavoring agents are Magnasweet ® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like.
- preservatives include potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chloride.
- Suitable diluents include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing.
- examples of diluents include microcrystalline cellulose, such as Avicel ® PHlOl and Avicel ® PH 102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose ® DCL21; dibasic calcium phosphate such as Emcompress ® ; mannitol; starch; sorbitol; sucrose; and glucose.
- Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross-povidone, sodium starch glycolate, and mixtures thereof.
- effervescent agents include effervescent couples such as an organic acid and a carbonate or bicarbonate.
- Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts.
- Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate.
- only the sodium bicarbonate component of the effervescent couple may be present.
- compositions of the invention comprise particles of at least one nanoparticulate kinase inhibitor, such as LS 104 (or a salt or derivative thereof), which have an effective average particle size of less than about 2000 nm (i.e., 2 microns), less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 990 nm, less than about 980 nm, less than about 970 nm, less than about 960 nm, less than about 950 nm, less than about 940 nm, less than about 930 nm, less than about 920 nm, less than about 910 nm, less than about 900 nm, less than about 890 nm, less than about 2000 nm
- an effective average particle size of less than about 2000 nm it is meant that at least 50% of the kinase inhibitor, such as LS104, particles have a particle size less than the effective average, by weight (or by other suitable measurement techniques, such as by volume, number, etc.), i.e., less than about 2000 nm, 1900 nm, 1800 nm, etc., when measured by the above-noted techniques.
- At least about 60%, at least about 70%, at least about 80% at least about 90%, at least about 95%, or at least about 99% of the kinase inhibitor, such as LS 104, particles have a particle size of less than the effective average, i.e., less than about 2000 nm, 1900 nm, 1800 nm, 1700 nm, etc.
- the value for D50 of a nanoparticulate kinase inhibitor, such as LS 104 composition is the particle size below which 50% of the kinase inhibitor particles fall, by weight.
- D90 is the particle size below which 90% of the kinase inhibitor particles fall, by weight.
- kinase inhibitor such as LS 104 or a salt or derivative thereof
- one or more surface stabilizers may vary.
- the optimal amount of the individual components can depend, for example, upon the particular kinase inhibitor selected, the hydrophilic lipophilic balance (HLB), melting point, and the surface tension of water solutions of the stabilizer, etc.
- the concentration of the kinase inhibitor may be present from about 99.5% to about 0.001%, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight, based on the total combined dry weight of the kinase inhibitor and at least one surface stabilizer, not including other excipients.
- the concentration of the at least one surface stabilizer may be present from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, or from about 10% to about 99.5%, by weight, based on the total combined dry weight of the kinase inhibitor and at least one surface stabilizer, not including other excipients.
- LS 104 tablet formulations are given below. These examples are not intended to limit the claims in any respect, but rather to provide exemplary tablet formulations of LS 104 which can be utilized in the methods of the invention. Such exemplary tablets may also include a coating agent.
- the invention provides injectable compositions comprising at least one nanoparticulate small molecule kinase inhibitor, such as LS 104, that may include high drug concentrations in low injection volumes, with rapid drug dissolution upon administration.
- the injectable nanoparticulate kinase inhibitors, such as LS 104 formulations of the invention may eliminate the need to use solubilizers such as polyoxyl 60 hydrogenated castor oil (HCO-60).
- Exemplary injectable compositions comprises, base on % w/w: Small molecule, synthetic kinase inhibitor such as LS 104: 5 - 50% Povidone polymer: 0.1 - 50%
- Preservatives 0.05 - 0.25% pH adjusting agent: pH about 6 to about 7
- Exemplary preservatives include methylparaben (about 0.18% based on % w/w), propylparaben (about 0.02% based on % w/w), phenol (about 0.5% based on % w/w), and benzyl alcohol (up to 2% v/v).
- An exemplary pH adjusting agent is sodium hydroxide
- an exemplary liquid carrier is sterile water for injection.
- Other useful preservatives, pH adjusting agents, and liquid carriers are well-known in the art.
- compositions comprising at least one nanoparticulate kinase inhibitor can be made using, for example, milling or attrition (including but not limited to wet milling), homogenization, precipitation, freezing, template emulsion techniques, supercritical fluid techniques, nano-electrospray techniques, or any combination thereof.
- milling or attrition including but not limited to wet milling
- homogenization precipitation
- freezing template emulsion techniques
- supercritical fluid techniques nano-electrospray techniques, or any combination thereof.
- Exemplary methods of making nanoparticulate compositions are described in the '684 patent. Methods of making nanoparticulate compositions are also described in U.S. Patent No. 5,518,187 for "Method of Grinding Pharmaceutical Substances;" U.S. Patent No. 5,718,388 for "Continuous Method of Grinding Pharmaceutical Substances;” U.S. Patent No.
- the resultant nanoparticulate kinase inhibitor compositions or dispersions can be utilized in solid or liquid dosage formulations, such as injectable form, liquid dispersions, gels, aerosols, ointments, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations, etc.
- Milling an kinase inhibitor, such as LS 104 or a salt or derivative thereof, to obtain a nanoparticulate kinase inhibitor dispersion comprises dispersing the kinase inhibitor particles in a liquid dispersion medium in which the kinase inhibitor is poorly soluble, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the kinase inhibitor to the desired effective average particle size.
- the dispersion medium can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol.
- a preferred dispersion medium is water.
- the kinase inhibitor particles can be reduced in size in the presence of at least one surface stabilizer.
- kinase inhibitor particles can be contacted with one or more surface stabilizers after attrition.
- Other compounds, such as a diluent, can be added to the kinase inhibitor /surface stabilizer composition during the size reduction process.
- Dispersions can be manufactured continuously or in a batch mode.
- the grinding media can comprise particles that are preferably substantially spherical in shape, e.g., beads, consisting essentially of polymeric or copolymeric resin.
- the grinding media can comprise a core having a coating of a polymeric or copolymeric resin adhered thereon.
- suitable polymeric or copolymeric resins are chemically and physically inert, substantially free of metals, solvent, and monomers, and of sufficient hardness and friability to enable them to avoid being chipped or crushed during grinding.
- Suitable polymeric or copolymeric resins include crosslinked polystyrenes, such as polystyrene crosslinked with divinylbenzene; styrene copolymers; polycarbonates; polyacetals, such as DelrinTM (E.I. du Pont de Nemours and Co.); vinyl chloride polymers and copolymers; polyurethanes; polyamides; poly(tetrafluoroethylenes), e.g., Teflon® (E.I.
- du Pont de Nemours and Co. and other fluoropolymers
- high density polyethylenes polypropylenes
- cellulose ethers and esters such as cellulose acetate
- polyhydroxymethacrylate polyhydroxyethyl acrylate
- silicone-containing polymers such as polysiloxanes and the like.
- the polymer can be biodegradable.
- biodegradable polymers or copolymers include poly(lactides), poly(glycolide) copolymers of lactides and glycolide, polyanhydrides, poly(hydroxyethyl methacylate), poly(imino carbonates), poly(N-acylhydroxyproline)esters, poly(N-palmitoyl hydroxyproline) esters, ethylene -vinyl acetate copolymers, poly(orthoesters), poly(caprolactones), and poly(phosphazenes).
- contamination from the media itself advantageously can metabolize in vivo into biologically acceptable products that can be eliminated from the body.
- the grinding media preferably ranges in size from about 0.01 to about 3 mm.
- the grinding media is preferably from about 0.02 to about 2 mm, and more preferably from about 0.03 to about 1 mm in size.
- the polymeric or copolymeric resin can have a density from about 0.8 to about 3.0 g/cm 3 .
- the particles are made continuously.
- Such a method comprises continuously introducing a composition according to the invention into a milling chamber, contacting the composition according to the invention with grinding media while in the chamber to reduce the particle size of the composition according to the invention, and continuously removing the nanoparticulate composition according to the invention nanoparticles from the milling chamber.
- the grinding media is separated from the milled nanoparticulate composition according to the invention nanoparticles using conventional separation techniques, in a secondary process such as by simple filtration, sieving through a mesh filter or screen, and the like. Other separation techniques such as centrifugation may also be employed.
- Another method of forming the desired composition comprising at least one nanoparticulate kinase inhibitor, such as LS 104 or a salt or derivative thereof, is by microprecipitation.
- This is a method of preparing stable dispersions of poorly soluble active agents in the presence of one or more surface stabilizers and one or more colloid stability enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal impurities.
- Such a method comprises, for example: (1) dissolving the kinase inhibitor in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer; and (3) precipitating the formulation from step (2) using an appropriate non-solvent.
- the method can be followed by removal of any formed salt, if present, by dialysis or diafiltration and concentration of the dispersion by conventional means.
- Exemplary homogenization methods of preparing active agent nanoparticulate compositions are described in U.S. Patent No. 5,510,118, for "Process of Preparing Therapeutic Compositions Containing Nanoparticles.” Such a method comprises dispersing particles of an LS 104, (or a salt or derivative thereof), in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size of an LS 104, (or a salt or derivative thereof), in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size of an LS 104, (or a salt or derivative thereof), in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size of an LS 104, (or a salt or derivative thereof), in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size of an LS 104, (or a salt or derivative thereof), in a liquid dispersion
- WASH 1899464 1 kinase inhibitor to the desired effective average particle size.
- the particles can be reduced in size in the presence of at least one surface stabilizer.
- the kinase inhibitor particles can be contacted with one or more surface stabilizers either before or after attrition.
- Other compounds, such as a diluent, can be added to the kinase inhibitor /surface stabilizer composition either before, during, or after the size reduction process.
- Dispersions can be manufactured continuously or in a batch mode.
- nanoparticulate kinase inhibitor such as LS 104 (or a salt or derivative thereof), composition
- SFL liquid
- This technology comprises an organic or organoaqueous solution of kinase inhibitor with stabilizers, which is injected into a cryogenic liquid, such as liquid nitrogen.
- the droplets of the LS 104 solution freeze at a rate sufficient to minimize crystallization and particle growth, thus formulating nanostructured LS 104 particles.
- the nanoparticulate kinase inhibitor particles can have varying particle morphology.
- the nitrogen and solvent are removed under conditions that avoid agglomeration or ripening of the kinase inhibitor particles.
- URF ultra rapid freezing
- Template emulsion creates nanostructured kinase inhibitor or derivative particles with controlled particle size distribution and rapid dissolution performance.
- the method comprises an oil-in-water emulsion that is prepared, then swelled with a non-aqueous solution comprising the kinase inhibitor and stabilizers.
- the particle size distribution of kinase inhibitor is a direct result of the size of the emulsion droplets prior to loading with the kinase inhibitor, a property which can be controlled and optimized in this process.
- solvents and stabilizers emulsion stability is achieved with no or suppressed Ostwald ripening. Subsequently, the solvent and water are removed, and the stabilized nanostructured kinase inhibitor particles are
- WASH 1899464 1 recovered.
- Various kinase inhibitor particles morphologies can be achieved by appropriate control of processing conditions.
- Nanop articulate compositions can also be made in methods utilizing supercritical fluids.
- a inase inhibitor such as LS 104
- a solution or vehicle which can also contain at least one surface stabilizer.
- the solution and a supercritical fluid are then co-introduced into a particle formation vessel. If a surface stabilizer was not previously added to the vehicle, it can be added to the particle formation vessel
- the temperature and pressure are controlled, such that dispersion and extraction of the vehicle occur substantially simultaneously by the action of the supercritical fluid.
- Chemicals described as being useful as supercritical fluids include carbon dioxide, nitrous oxide, sulphur hexafluoride, xenon, ethylene, chlorotrifluoromethane, ethane, and trifluoromethane.
- Examples of known supercritical methods of making nanoparticles include International Patent Application No. WO 97/144407 to Pace et al, published on April 24, 1997, which refers to particles of water insoluble biologically active compounds with an average size of 100 nm to 300 nm prepared by dissolving the compound in a solution and then spraying the solution into compressed gas, liquid, or supercritical fluid in the presence of appropriate surface stabilizers.
- U.S. Patent No. 6,406,718 to Cooper et al. describes a method for forming a particulate fluticasone propionate product comprising the co-introduction of a supercritical fluid and a vehicle containing at least fluticasone propionate in solution or suspension into a particle formation vessel, the temperature and pressure in which are controlled, such that dispersion and extraction of the vehicle occur substantially simultaneously by the action of the supercritical fluid.
- Chemicals described as being useful as supercritical fluids include carbon dioxide, nitrous oxide, sulphur hexafluoride, xenon, ethylene, chlorotrifluoromethane, ethane, and trifluoromethane.
- the supercritical fluid may optionally contain one or more modifiers, such as methanol, ethanol, ethyl acetate, acetone, acetonitrile or any mixture thereof.
- a supercritical fluid modifier is a chemical which, when added to a supercritical fluid, changes the intrinsic properties of the supercritical fluid in or around the critical point. According to Cooper et al., the fluticasone propionate particles produced using supercritical fluids have a particle size range of 1 to 10 microns, preferably 1 to 5 microns.
- a liquid is pushed through a very small charged, usually metal, capillary.
- This liquid contains the desired substance, e.g., a kinase inhibitor (or "analyte"), dissolved in a large amount of solvent, which is usually much more volatile than the analyte. Volatile acids, bases or buffers are often added to this solution as well.
- the analyte exists as an ion in solution either in a protonated form or as an anion. As like charges repel, the liquid pushes itself out of the capillary and forms a mist or an aerosol of small droplets about 10 ⁇ m across.
- This jet of aerosol droplets is at least partially produced by a process involving the formation of a Taylor cone and a jet from the tip of this cone.
- a neutral carrier gas such as nitrogen gas, is sometimes used to help nebulize the liquid and to help evaporate the neutral solvent in the small droplets.
- the small droplets evaporate, suspended in the air, the charged analyte molecules are forced closer together.
- the drops become unstable as the similarly charged molecules come closer together and the droplets once again break up. This is referred to as Coulombic fission because it is the repulsive Coulombic forces between charged analyte molecules that drive it. This process repeats itself until the analyte is free of solvent and is a lone ion.
- the electrospray method may be employed to deposit single particles on surfaces, e.g., particles of a kinase inhibitor. This is accomplished by spraying colloids and making sure that on average there is not more than one particle per droplet. Consequent drying of the surrounding solvent results in an aerosol stream of single particles of the desired type.
- the ionizing property of the process is not crucial for the application but may be put to use in electrostatic precipitation of the particles.
- the invention provides a method of increasing bioavailability (e.g. , increasing the plasma levels) of an kinase inhibitor such as LS 104 (or a salt or derivative thereof), in a subject.
- a method comprises orally administering to a subject an effective amount of a composition comprising a nanoparticulate kinase inhibitor.
- the nanoparticulate kinase inhibitor such as LS 104
- composition in accordance with standard pharmacokinetic practice, is expected to exhibit a bioavailability that is about 50% greater, about 40% greater, about 30% greater, about 20% greater, or about 10% greater than a conventional dosage form.
- compositions when tested in fasting subjects in accordance with standard pharmacokinetic practice are proposed to produces a maximum blood plasma concentration profile in less than about 6 hours, less than about 5 hours, less than about 4 hours, less than about 3 hours, less than about 2 hours, less than about 1 hour or less than about 30 minutes after the initial dose of the composition.
- the compositions of the invention may be useful in the treatment of cell proliferative diseases such as cancer, for example leukemias such as CML and ALL, and myeloproliferative diseases, such as PV, ET and IMF.
- compositions of the invention comprising at least one nanoparticulate kinase inhibitor, such as LS 104 (or a salt or derivative thereof), can be administered to a subject via any conventional means including, but not limited to, orally, rectally, ocularly, parenterally (e.g., intravenous, intramuscular, or subcutaneous), intracisternally, pulmonary, intravaginally, intraperitoneally, locally (e.g., powders, ointments or drops), or as a buccal or nasal spray. In some embodiments, parenteral administration is preferred.
- parenteral administration is preferred.
- the term "subject” is used to mean an animal, preferably a mammal, including a human or non-human.
- compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles including water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions comprising at least one nanoparticulate kinase inhibitor may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
- adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
- Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like.
- Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
- Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders, and granules.
- the active agent is admixed with at least one of the following: (a) one or more inert excipients (or carriers), such as sodium citrate or dicalcium phosphate; (b) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (c) binders, such as carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (d) humectants, such as glycerol; (e) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (f) solution retarders, such as paraffin; (g) absorption accelerators, such as paraffin; (g) absorption accelerators, such as
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
- the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers.
- Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3 -butyl eneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
- oils such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil
- glycerol tetrahydrofurfuryl alcohol
- polyethyleneglycols fatty acid esters of sorbitan, or mixtures of these substances, and the like.
- the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- “Therapeutically effective amount” as used herein with respect to, for example a kinase inhibitor such as LS 104 dosage shall mean that dosage that provides the specific pharmacological response for which an LS 104 is administered in a significant number of subjects in need of such treatment. It is emphasized that "therapeutically effective amount,” administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a "therapeutically effective amount” by those skilled in the art. It is to be further understood that LS 104 dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
- a kinase inhibitor such as LS 104 can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, or prodrug form. Actual dosage levels of kinase inhibitor such as LS 104 in the nanoparticulate compositions of the invention may be varied to obtain an amount of a kinase inhibitor such as LS 104 that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered kinase inhibitor such as LS104, the desired duration of treatment, and other factors.
- Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts.
- NBD nanoparticulate dispersion formulation
- the initial formulation screening was done using a low energy roller mill (Stoneware) approach.
- the grinding media utilized was 0.8 mm yittrium treated zirconia
- WASH 1899464 1 Light microscopy was performed using a Leica Light microscope with 10Ox objective. All particle sizes were measured using the Horiba LA 910 with deionized (DI) water as the diluent and 30 seconds sonication.
- DI deionized
- the first comprised Poloxamer 338 (Pluronic F108) as the stabilizer. Large crystals were observed at the end of the process. This may be a result of crystal growth (Ostwald ripening), suggesting that this stabilizer may not be optimal under certain milling parameters (i.e., the particular drug concentration and surface stabilizer concentration utilized).
- the second formulation comprised Polysorbate 80 (Tween 80). A dispersion comprising small, well-dispersed particles was observed at the end of the process.
- the third formulation comprised hydroxy propyl cellulose (HPC-SL). This formulation also comprised small, well- dispersed particles.
- the fourth formulation comprised a mixture of povidone K- 12 (Plasdone K- 12, a low molecular weight grade polyvinylpyrrolidone) and sodium deoxycholate. This formulation also comprised small, well-dispersed particles and the end of the process. The results are summarized in Table 1 below.
- Terminal sterilization was achieved using gamma irradiation.
- the final product was packed into a vial, which is also terminally irradiated.
- Stability studies e.g., 3 months, 6 months and 12 months under various temperature and humidity conditions may be performed on several batches.
- Table 3 details additional exemplary nanoparticulate LS104 formulations. All of these formulations were prepared using the NanoMill-01 (NanoMill Systems, King of Prussia, PA; see e.g., U.S. Patent No. 6,431,478), along with 500 micron PolyMill® attrition media (Dow Chemical). Again, light microscopy was performed using a Leica Light microscope with IOOX oil objective. All particle sizes were determined using the Horiba LA 910 with distilled, deionized water as the diluent and 30 second sonication. Table 3, Column 1 shows the formulation; Column 2 shows both the mean and D90 particle size (PS); Column
- WASH 1899464 1 3 includes microscopy observations; Column 4 shows milling time; Column 5 indicates mill size; Column 6, indicates mill load; Column 7 shows mill speed; and Column 8 contains comments regarding the formulation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009515607A JP2009540010A (en) | 2006-06-13 | 2007-06-12 | Nanoparticulate kinase inhibitor preparation |
AU2007257667A AU2007257667A1 (en) | 2006-06-13 | 2007-06-12 | Nanoparticulate kinase inhibitor formulations |
EP07798449A EP2043606A2 (en) | 2006-06-13 | 2007-06-12 | Nanoparticulate kinase inhibitor formulations |
CA002654909A CA2654909A1 (en) | 2006-06-13 | 2007-06-12 | Nanoparticulate kinase inhibitor formulations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81296006P | 2006-06-13 | 2006-06-13 | |
US60/812,960 | 2006-06-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007146943A2 true WO2007146943A2 (en) | 2007-12-21 |
WO2007146943A3 WO2007146943A3 (en) | 2008-05-29 |
Family
ID=38832788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/071011 WO2007146943A2 (en) | 2006-06-13 | 2007-06-12 | Nanoparticulate kinase inhibitor formulations |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2043606A2 (en) |
JP (1) | JP2009540010A (en) |
KR (1) | KR20090018864A (en) |
CN (1) | CN101500540A (en) |
AU (1) | AU2007257667A1 (en) |
CA (1) | CA2654909A1 (en) |
TW (1) | TW200816987A (en) |
WO (1) | WO2007146943A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013105894A1 (en) * | 2012-01-13 | 2013-07-18 | Xspray Microparticles Ab | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
US9084727B2 (en) | 2011-05-10 | 2015-07-21 | Bend Research, Inc. | Methods and compositions for maintaining active agents in intra-articular spaces |
US9757464B2 (en) | 2009-03-05 | 2017-09-12 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX371209B (en) * | 2012-01-13 | 2020-01-22 | Xspray Microparticles Ab | A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component. |
TWI535784B (en) | 2014-08-26 | 2016-06-01 | 財團法人工業技術研究院 | Shear thickening formulation and composite material employing the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4820101A (en) * | 2000-04-13 | 2001-10-30 | Hsc Res Dev Lp | Novel compounds for modulating cell proliferation |
EP1490025B1 (en) * | 2002-03-20 | 2008-02-13 | Elan Pharma International Limited | Nanoparticulate compositions of map kinase inhibitors |
-
2007
- 2007-06-12 WO PCT/US2007/071011 patent/WO2007146943A2/en active Application Filing
- 2007-06-12 JP JP2009515607A patent/JP2009540010A/en active Pending
- 2007-06-12 CN CNA2007800298841A patent/CN101500540A/en active Pending
- 2007-06-12 EP EP07798449A patent/EP2043606A2/en not_active Withdrawn
- 2007-06-12 CA CA002654909A patent/CA2654909A1/en not_active Abandoned
- 2007-06-12 AU AU2007257667A patent/AU2007257667A1/en not_active Abandoned
- 2007-06-12 KR KR1020097000297A patent/KR20090018864A/en not_active Application Discontinuation
- 2007-06-13 TW TW096121317A patent/TW200816987A/en unknown
Non-Patent Citations (1)
Title |
---|
None |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9757464B2 (en) | 2009-03-05 | 2017-09-12 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
US9084727B2 (en) | 2011-05-10 | 2015-07-21 | Bend Research, Inc. | Methods and compositions for maintaining active agents in intra-articular spaces |
US10314830B2 (en) | 2012-01-13 | 2019-06-11 | Xspray Microparticles Ab | Pharmaceutical compositions |
US10555937B2 (en) | 2012-01-13 | 2020-02-11 | Xspray Microparticles Ab | Pharmaceutical compositions |
AU2013208323B2 (en) * | 2012-01-13 | 2017-07-06 | Xspray Microparticles Ab | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
WO2013105895A1 (en) * | 2012-01-13 | 2013-07-18 | Xspray Microparticles Ab | A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
US9827230B2 (en) | 2012-01-13 | 2017-11-28 | Xspray Microparticles Ab | Pharmaceutical compositions |
US9833443B2 (en) | 2012-01-13 | 2017-12-05 | Xspray Microparticles Ab | Pharmaceutical compositions |
US9833442B2 (en) | 2012-01-13 | 2017-12-05 | Xspray Microparticles Ab | Pharmaceutical compositions |
US10143683B2 (en) | 2012-01-13 | 2018-12-04 | Xspray Microparticles Ab | Pharmaceutical compositions |
WO2013105894A1 (en) * | 2012-01-13 | 2013-07-18 | Xspray Microparticles Ab | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
US10314829B2 (en) | 2012-01-13 | 2019-06-11 | Xspray Microparticles Ab | Pharmaceutical compositions |
AU2018200928B2 (en) * | 2012-01-13 | 2019-07-18 | Xspray Microparticles Ab | A pharmaceutical composition comprising stable, amorphous hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
US9456992B2 (en) | 2012-01-13 | 2016-10-04 | Xspray Microparticles Ab | Pharmaceutical composition comprising stable, amorphous, hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix forming component |
US10561644B2 (en) | 2012-01-13 | 2020-02-18 | Xspray Microparticles Ab | Pharmaceutical compositions |
US10561643B2 (en) | 2012-01-13 | 2020-02-18 | Xspray Microparticles Ab | Pharmaceutical compositions |
US10561645B2 (en) | 2012-01-13 | 2020-02-18 | Xspray Microparticles Ab | Pharmaceutical compositions |
US10772877B2 (en) | 2012-01-13 | 2020-09-15 | Xspray Microparticles Ab | Pharmaceutical compositions |
US11241419B2 (en) | 2012-01-13 | 2022-02-08 | Xspray Pharma Ab | Pharmaceutical compositions |
US11376243B2 (en) | 2012-01-13 | 2022-07-05 | Xspray Pharma Ab | Pharmaceutical compositions |
US11426391B2 (en) | 2012-01-13 | 2022-08-30 | Xspray Pharma Ab | Pharmaceutical compositions |
US11517562B2 (en) | 2012-01-13 | 2022-12-06 | Xspray Pharma Ab | Pharmaceutical compositions |
US11963951B2 (en) | 2012-01-13 | 2024-04-23 | Xspray Pharma Ab | Pharmaceutical compositions |
Also Published As
Publication number | Publication date |
---|---|
CN101500540A (en) | 2009-08-05 |
EP2043606A2 (en) | 2009-04-08 |
JP2009540010A (en) | 2009-11-19 |
AU2007257667A1 (en) | 2007-12-21 |
WO2007146943A3 (en) | 2008-05-29 |
TW200816987A (en) | 2008-04-16 |
KR20090018864A (en) | 2009-02-23 |
CA2654909A1 (en) | 2007-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11253478B2 (en) | Reduction of flake-like aggregation in nanoparticulate active agent compositions | |
US20080213374A1 (en) | Nanoparticulate sorafenib formulations | |
EP1895984B1 (en) | Nanoparticulate imatinib mesylate formulations | |
AU2006309295B2 (en) | Nanoparticulate acetaminophen formulations | |
US20070148100A1 (en) | Nanoparticulate aripiprazole formulations | |
US20060159767A1 (en) | Nanoparticulate bicalutamide formulations | |
EP1898882B1 (en) | Nanoparticulate ebastine formulations | |
US20070042049A1 (en) | Nanoparticulate benidipine compositions | |
US20100221327A1 (en) | Nanoparticulate azelnidipine formulations | |
EP2043606A2 (en) | Nanoparticulate kinase inhibitor formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780029884.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07798449 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2654909 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5030/KOLNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009515607 Country of ref document: JP Ref document number: 2007257667 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097000297 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2007257667 Country of ref document: AU Date of ref document: 20070612 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007798449 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |